Replay available

Schrodinger, Inc. (SDGR) Q1 2026 Earnings Call

Schrodinger, Inc. (NASDAQ: SDGR) Q1 2026 earnings conference call, held 2026-05-05. Replay captured from the company's public earnings webcast.

Tue, May 5, 2026 at 4:30 PMendedReplay
Schrodinger, Inc. (SDGR) Q1 2026 Earnings Call

Investor webinar replay

Latest press releases

Companies on this event

Featured Presenters

Jaron Madden

Chief Corporate Affairs Officer and Head of Investor Relations

Rami Fareed

Chief Executive Officer

Richie Jane

Chief Financial Officer

Karen Akinsanya

President, Head of Therapeutics R&D and Chief Strategy Officer, Partnerships

Pat Lorton

Chief Technology and Chief Operating Officer

Manny Ferruhar

Analyst (Learing Partners)

Brendan Smith

Analyst (TD Cowan)

Michael Riskin

Analyst (Bank of America)

Michael Yee

Analyst (UBS Securities)

Matt Hewitt

Analyst (Craig-Hallam)

Replay transcript excerpt

Thank you for standing by. Welcome to Schrodinger's conference call to review first quarter 2026 financial results. My name is Rob and I'll be your operator for today's call. All lines have been placed on mute to prevent any background noise. After the speaker's remarks, there will be a question and answer session. If you would like to ask a question during this time, simply press star, then the number one on your telephone keypad. Please be advised that this call is being recorded at the company's request. Now, I would like to introduce your host for today's conference, Ms. Jaron Madden, Chief Corporate Affairs Officer and Head of Investor Relations. Please go ahead. Thank you and good afternoon, everyone. Welcome to today's call during which we will provide an update on the company and review our first quarter 2026 financial results. Earlier today, we issued a press release summarizing these results and progress across the company, which is available on our website at schrodinger.com. During today's call, management will make statements that are forward-looking and made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, including without limitation, Statements related to our outlook for the full year 2026, our plans to accelerate the growth of our software business and advance our therapeutics portfolio, the clinical potential and properties of our and our collaborators' compounds, use of our cash resources, as well as our future expenses. These forward-looking statements reflect our current views about our plans, intentions, expectations, strategies, and prospects. which are based on the information currently available to us and on assumptions we have made. Actual results may differ materially due to a number of importa...

More from Schrodinger, Inc.